Inactive Instrument

Amarantus BioSciences Inc OTC Bulletin Board

Equities

US02300Q1058

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

2022	Sector Update: Financial Stocks Still Adding to Wednesday Declines	MT
2020	Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	CI

Amarantus BioSciences Inc : Amarantus BioSciences to be Interviewed on The Big Biz Radio Show

January 12, 2012 at 01:50 pm EST

MarketScreener.com By

Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced the company will be a featured guest on The Big Biz Radio Show on Friday, January 13, 2012 at 1:10 PM PDT. The live broadcast can be accessed via the show's website: http://bigbizshow.com/media/

The Big Biz Show is a nationwide radio broadcast featuring commentators Bob Sullivan and Russ Nailz who discuss topics including current events, business trends, investment opportunities, innovations in headline making industries, and hot stock picks.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

IR Sense
Remy Barnarda, 415-203-6386
Remy@irsense.com

Latest news about Amarantus BioSciences Inc

Sector Update: Financial Stocks Still Adding to Wednesday Declines	22-03-30	MT
Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	20-07-27	CI
Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.	20-01-29	CI
Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products	20-01-02	CI
Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics	19-11-21	CI
Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc	19-10-24	CI
Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	19-10-23	CI
Amarantus Enters into Letter of Intent with the Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation	19-06-25	CI
Amarantus BioScience Holdings, Inc. Announces Positive Pre-Clinical Data for Manf in Wolfram Syndrome	19-06-18	CI
Amarantus Hires Evolution Venture Partners To Evaluate Alternatives For Expansion Into Legal Hemp	19-05-28	CI
Todos Medical Ltd. (OTCPK:TOMD.F) exercised the option to acquire the remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc..	19-04-21	CI
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries	19-01-11	CI
Todos Medical Ltd. Enters into Joint Venture Agreement with Amarantus to Develop Alzheimer’S Blood Diagnostic Lympro Test 2.0	18-12-03	CI
Coeptis Pharmaceuticals, Inc. entered into a binding agreement to acquire Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	18-11-27	CI
Amarantus Enters into Exclusive Option Agreement with Leipzig University to License IP Covering Alzheimer's Blood Diagnostic LymPro Test 2.0 Blood Test Vs. Amyloid Pet	18-05-04	CI
Amarantus Bioscience Holdings, Inc. Names Michael T. Ropacki as Chief Medical Advisor to Alzheimer's Blood Diagnostic LymPro Test Program	18-04-16	CI
Amarantus BioScience Holdings, Inc. (‘AMBS’) acquired certain assets of Avant Diagnostics, Inc. (‘Avant’) for $0.05 million.	18-04-05	CI
Amarantus BioScience Holdings, Inc. Announces Executive Changes	18-04-05	CI
Amarantus Bioscience Holdings, Inc. Announces Temporary Relocation of Headquarters to WeWork	18-04-02	CI
Amarantus BioScience Holdings, Inc. announced that it expects to receive $1.5 million in funding	18-02-25	CI
Amarantus Bioscience Holdings, Inc & MANF Therapeutics, Inc. Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF	17-12-14	CI
Amarantus Bioscience Holdings, Inc announced that it expects to receive $0.5 million in funding	17-11-16	CI
Amarantus Bioscience Holdings, Inc cancelled the acquisition of biomedical assets from SeD BioMedical Inc.	17-09-29	CI
Amarantus Bioscience Holdings, Inc Announces Resignation of Robert H. Trapp and Ronald Wei Resigned as Members of the Board of Directors	17-05-09	CI
Amarantus Bioscience Holdings, Inc. Establishes Two New Subsidiaries	17-04-17	CI

Chart Amarantus BioSciences Inc

Duration

Period

More charts

Company Profile

Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. It has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Companyâs wholly owned subsidiary Cutanogen Corporation. The Companyâs wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research